Charles River Laboratories International, Inc. (CRL)
$
210.48
-1.20 (-0.57%)
Key metrics
Financial statements
Free cash flow per share
11.0473
Market cap
10.9 Billion
Price to sales ratio
2.7196
Debt to equity
0.7727
Current ratio
1.3656
Income quality
-9.4133
Average inventory
291.1 Million
ROE
-0.0249
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,718,168,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.06 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $126,288,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,822,642,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.33 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $155.39 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 829,100.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $10,358,872,336.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.
Is Charles River Laboratories International, Inc. (CRL) a good investment?
Investing in Charles River Laboratories International, Inc. (CRL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Charles River Laboratories International, Inc. (CRL)'s stock forecast?
Analysts predict Charles River Laboratories International, Inc. stock to fluctuate between $91.86 (low) and $228.88 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Charles River Laboratories International, Inc.'s market capitalization?
As of 2026-01-30, Charles River Laboratories International, Inc.'s market cap is $10,358,872,336, based on 49,215,471 outstanding shares.
How does Charles River Laboratories International, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Charles River Laboratories International, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Charles River Laboratories International, Inc. (CRL) stock?
To buy Charles River Laboratories International, Inc. (CRL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRL. Place an order (Market, Limit, etc.).
What is the best time to invest in Charles River Laboratories International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Charles River Laboratories International, Inc. perform in the last earnings report?
Revenue: $4,049,989,000 | EPS: $0.20 | Growth: 0%.
Where can I find Charles River Laboratories International, Inc.'s investor relations reports?
Visit https://www.criver.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Charles River Laboratories International, Inc.?
You can explore historical data from here
What is the all-time high and low for Charles River Laboratories International, Inc. stock?
All-time high: $460.21 (2021-09-24) | All-time low: $91.86 (2025-04-11).
What are the key trends affecting Charles River Laboratories International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call.
prnewswire.com
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
reuters.com
Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of the animals used in drug safety testing.
businesswire.com
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.
globenewswire.com
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
globenewswire.com
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
globenewswire.com
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483)
prnewswire.com
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
globenewswire.com
SAN FRANCISCO, Jan. 02, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026.
zacks.com
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
See all news
